Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients. (17th August 2013)

• Record Type: Journal Article
• Authors: Wimmer, Cosmas D.; Angele, Martin K.; Schwarz, Bettina; Pratschke, Sebastian; Rentsch, Markus; Khandoga, Andrej; Guba, Markus; Jauch, Karl‐Walter; Bruns, Christiane; Graeb, Christian
• Is Part Of: Transplant international. Volume 26:Number 10(2013:Oct.)
• Page Start: 999
• Page End: 1006
• Publication Date: 2013-08-17
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12165
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12165-abs-0001"> <title>Summary</title> <p> <italic>De novo</italic> malignancies are a major cause of late death after liver transplantation. Aim of the present study was to determine whether use of cyclosporine versus tacrolimus affects long‐term tumor incidence considering potential confounders. <italic>De novo</italic> malignancies in 609 liver transplant recipients at Munich Transplant Centre between 1985 and 2007 were registered. In 1996, the standard immunosuppressive regimen was changed from cyclosporine to tacrolimus. Different effects of those drugs on long‐term tumor incidence were analyzed in multivariate analysis. During 3765 patient years of follow‐up (median 4.78 years), 87 <italic>de novo</italic> malignancies occurred in 71 patients (mean age 47.5 ± 13.3 years, mean time after liver transplantation 5.7 ± 3.7 years). The cumulative incidence of <italic>de novo</italic> malignancies was 34.7% for all tumor entities after 15 years as compared to 8.9% for a nontransplanted population. The most frequent tumors observed were nonmelanoma skin cancers (44.83%). Moreover, post‐transplant lymphoid disease, oropharyngeal cancer (<italic>n</italic> = 6, 6.9%), upper gastrointestinal tract cancer (<italic>n</italic> = 4, 4.6%), lung cancer (<italic>n</italic> = 4, 4.6%), gynecological malignancies (<italic>n</italic> = 4, 4.6%), and kidney cancer (<italic>n</italic> = 3, 3.45%) were detected. Multivariate analysis revealed recipient age [hazards ratio (HR) 1.06], male gender (HR 1.73), and tacrolimus‐based immunosuppression (HR 2.06) as significant risk factors. Based on those results, a tacrolimus‐based immunosuppression should be discussed especially in older male patients. Whether reducing tacrolimus target levels may reduce the risk for de novo malignancies has yet to be determined in prospective trials.</p> </abstract>